



Number of Drugs Under Consideration by pCPA, 3-Month Quarterly Average, 2023 – Q2 2025



* Does not include drugs where negotiations were not pursued or subsequent pCPA attempts after the first attempt.


Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations> and CDA data collected from <https://www.cda-amc.ca/reimbursement-review-reports>.

Number of New pCPA Negotiations



Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations> and CDA data collected from <https://www.cda-amc.ca/reimbursement-review-reports>.


CDA Recommendation to pCPA Engagement, All Drugs



Does not include drugs where negotiations were not pursued or subsequent pCPA attempts after the first attempt.


Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations> and CDA data collected from <https://www.cda-amc.ca/reimbursement-review-reports>.

Number of Active pCPA Negotiations, 3-Month Quarterly Average, 2023 – Q2 2025




Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations>.

Number of Active pCPA Negotiations and Files Under Consideration, 3-Month Quarterly Average, 2023 – T2 2025




Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations>.

pCPA Total Time, All Drugs



Negotiations on BPG Target



BPG – Brand
Process Guidelines

N = number of completed negotiations

Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations>.